| Name | Title | Contact Details |
|---|
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
Hemarus is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hemagen Diagnostics is a Columbia, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
University Cancer & Blood Center’s highly skilled medical professionals, whose backgrounds include working at the nation’s leading cancer centers, provide every patient with the...
Ghost Lifestyle is a premium lifestyle brand of dietary supplements and sports nutrition products that encourages people to rethink the boundaries and lifestyles championed by traditional sports nutrition brands in exchange for an all-encompassing, fit...